These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12359877)

  • 21. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.
    Ouerfelli O; Warren JD; Wilson RM; Danishefsky SJ
    Expert Rev Vaccines; 2005 Oct; 4(5):677-85. PubMed ID: 16221069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
    Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
    ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
    Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
    Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbohydrate antigens as targets for active specific immunotherapy.
    Ragupathi G
    Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer.
    Croce MV; Segal-Eiras A
    Drugs Today (Barc); 2002 Nov; 38(11):759-68. PubMed ID: 12582459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
    Lo-Man R; Vichier-Guerre S; Perraut R; Dériaud E; Huteau V; BenMohamed L; Diop OM; Livingston PO; Bay S; Leclerc C
    Cancer Res; 2004 Jul; 64(14):4987-94. PubMed ID: 15256473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
    Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
    Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
    Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
    Sarkar S; Salyer AC; Wall KA; Sucheck SJ
    Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.
    Guo J; Jiang W; Li Q; Jaiswal M; Guo Z
    Carbohydr Res; 2020 Jun; 492():107999. PubMed ID: 32272238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of widely consumed botanicals as immunological adjuvants.
    Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
    Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
    Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
    Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
    Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
    Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
    J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.